New

Chrome Plugin Live! Redefine the way you read FinTwit 🚀 Install Now

You have successfully sign out
Loading...
Shape
Gilead Sciences, Inc.
GILD
Shape
US Flag

NASDAQ

EPS improving

EPS improving

109B

Drug Manufacturers - General

Next Earning date - 06 Nov 2024

109B

Drug Manufacturers - General

Next Earning date - 06 Nov 2024

87.90USD
Shape-0.86 ( -0.97%)
Market Open
favorite-chart

Relative Strenght

22
favorite-chart

Volume Buzz

-48%
favorite-chart

Earning Acce

No
favorite-chart

Dist 52w H.

2%

Quote Panel

Shape
Updated October 29, 2024
1W 0.62 % 1M 4.69 % 3M 13.50 % 1Y 17.56 %

Key Metrics

Shape
  • Market Cap

    109.43B


  • Shares Outstanding

    1.24B


  • Share in Float

    1.24B


  • Dividende

    3.08


  • Earning Date

    06 Nov 2024


  • Price Target

    87.9


  • Average Volume

    6.12M


  • Beta

    0.199


  • Range

    62.07-89.74


  • Industry

    Drug Manufacturers - General


  • Website

    https://www.gilead.com


  • Sector

    Healthcare


Fundamentals

Shape

18.67x

P/E Ratio

3.98x

P/S Ratio

6.05x

P/B Ratio

1.3

Debt/Equity

3.8%

Net Margin

$0.8

EPS

How GILD compares to sector?

P/E Ratio

Relative Strength

Shape

GILD

Sector

loading...

Top 5 RS in Group

Symbol

Company

RS

5-Day Perf.

Forecast

Shape

$28B

Shape304%

2025-Revenue

$5.23

Shape306%

2025-EPS

$10B

Shape195%

2025-EBITDA

Analyst rating

No Data Available

Last analyst upgrade/downgrade

Leerink Partners

upgrade

Previous: Not converted

2024-10-21

Now: Outperform

Bernstein

initialise

Previous: Not converted

2024-10-17

Now: Outperform

Wells Fargo

upgrade

Previous: Sector Perform

2024-10-07

Now: Overweight

Raymond James

upgrade

Previous: Not converted

2024-07-08

Now: Outperform

Earnings GrowthShape

status-upYoY

Current

Estimates

Q3.22

arrow
arrow

-28%

1.9
vs 2.65

Q4.22

arrow
arrow

+142%

1.67
vs 0.69

Q1.23

arrow
arrow

-35%

1.37
vs 2.12

Q2.23

arrow
arrow

-15%

1.34
vs 1.58

Q3.23

arrow
arrow

+21%

2.29
vs 1.9

Q4.23

arrow
arrow

+3%

1.72
vs 1.67

Q1.24

arrow
arrow

N/A

-1.32
vs 1.37

Q2.24

arrow
arrow

+50%

2.01
vs 1.34

Q3.24

arrow
arrow

-33%

1.53
vs 2.29

Q4.24

arrow
arrow

-9%

1.56
vs 1.72

Sales GrowthShape

status-upYoY

Current

Estimates

Q3.22

arrow
arrow

-5%

7B  vs 7.4B

Q4.22

arrow
arrow

+2%

7.4B  vs 7.2B

Q1.23

arrow
arrow

-4%

6.4B  vs 6.6B

Q2.23

arrow
arrow

+5%

6.6B  vs 6.3B

Q3.23

arrow
arrow

+0%

7B  vs 7B

Q4.23

arrow
arrow

-4%

7.1B  vs 7.4B

Q1.24

arrow
arrow

+5%

6.7B  vs 6.4B

Q2.24

arrow
arrow

+5%

6.9B  vs 6.6B

Q3.24

arrow
arrow

-1%

7B  vs 7B

Q4.24

arrow
arrow

+0%

7.1B  vs 7.1B

Return on EquityShape

status-upQoQ

Q3.22

arrow
arrow

+8%

0.08
vs 0.06

Q4.22

arrow
arrow

+8%

0.08
vs 0.08

Q1.23

arrow
arrow

+5%

0.05
vs 0.08

Q2.23

arrow
arrow

+5%

0.05
vs 0.05

Q3.23

arrow
arrow

+10%

0.1
vs 0.05

Q4.23

arrow
arrow

+6%

0.06
vs 0.1

Q1.24

arrow
arrow

-24%

-0.24
vs 0.06

Q2.24

arrow
arrow

+9%

0.09
vs -0.24

Institutionnal OwnershipShape

status-upQoQ

Q3.22

arrow
arrow

1664

1.7K
vs 1.7K

0%

Q4.22

arrow
arrow

1824

1.8K
vs 1.7K

10%

Q1.23

arrow
arrow

1784

1.8K
vs 1.8K

-2%

Q2.23

arrow
arrow

1741

1.7K
vs 1.8K

-2%

Q3.23

arrow
arrow

1727

1.7K
vs 1.7K

-1%

Q4.23

arrow
arrow

1820

1.8K
vs 1.7K

5%

Q1.24

arrow
arrow

1758

1.8K
vs 1.8K

-3%

Q2.24

arrow
arrow

1689

1.7K
vs 1.8K

-4%

Earnings Growth

Latest News